- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04764253
Examining the Individual Response to a Restricted Sodium Diet in Hypertensive Patients
Excessive dietary sodium intake is an independent risk factor for hypertension and cardiovascular disease. A vast array of efforts have tried to reduce sodium consumption based on evidence indicating a public health benefit. Yet this benefit has been questioned, mainly based on studies showing variability in individual responses to a sodium-restricted diet (SRD). The effects of an SRD on blood pressure vary, and adherence to an SRD is not optimal. The original Sodium Watchers Program (R01NR012967) was developed and implemented by Dr. Misook Chung (University of Kentucky). In this pilot study, the modified Sodium Watchers Program will propose improving adherence to an SRD through education and digital self-monitoring for daily sodium intake and blood pressure.
In addition, few studies have examined individuals' metabolic responses to the SRD. In a secondary analysis, we further will examine genetic variants associated with salt sensitivity and whether such a genetic component is associated with sodium excretion and BP control.
A total of 40 hypertensive patients will be randomly assigned to the intervention (n=20) or control group (n=20). The intervention group will receive 8-week education sessions remotely using a video conferencing program. All participants will collect a 24-hour urine specimen for sodium excretion and a total of 4.0ml of peripheral blood will be drawn for salt sensitivity during baseline visit. All participants will be asked to log their activities in real-time, including food intake and in-home BP monitoring using Fitbit and accompanied mobile app and BP monitor.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78229
- The University of Texas Health Science Center at San Antonio
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Systolic blood pressure of 120-159 mmHg or diastolic blood pressure of 80-99 mmHg, whether or not taking blood pressure medications.
- Smartphone with a data plan
- Valid email address
- Willing and able to participate in online study videoconferencing visits (Zoom)
- Reads and writes in English
Exclusion Criteria:
- Participating in another related research study
- Cardiovascular disease event (e.g. stroke, myocardial infarction) in prior 6 months
- Active cancer
- Recent hospitalization due to psychiatric condition or event
- Pregnancy or breastfeeding - current or planned during the study period
- Documented dementia
- Prisoners
- Diabetes Diagnosis
- Heart Failure Diagnosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Modified Sodium Watcher Program + Digital Self-Monitoring
|
Participants randomized to the experimental group will be asked to follow the modified Sodium Watchers Program intervention along with goal setting for low salt foods.
Each participant will be registered to assign a unique ID in the Connected Health Platform developed by the Center on Smart and Connected Health Technologies at UT Health Science Center San Antonio and each account from the individuals' wireless and wearable devices (Fitbit and BP monitor) will be connected to his or her unique ID through this platform.
Participants will be instructed to log their activities in real-time, including food intake and in-home BP monitoring using Fitbit and accompanied mobile app and BP monitor.
Through the Connected Health Platform, the Fitbit app and BP monitor will transmit the data of the intervention group to the research team.
|
|
Active Comparator: Usual care + Digital Self-Monitoring
|
Participants randomized to the control group will be asked to follow usual care which is based on their routine medical and nursing care for hypertension that consists of a recommendation to follow a sodium-restricted diet and take medications as prescribed.
The participants will receive wireless and wearable devices (Fitbit wristband, BP monitor).
Each participant will be registered to assign a unique ID in the Connected Health Platform at the baseline and each account from the individual's wireless and wearable devices (Fitbit and BP monitor) will be connected to their unique ID through this platform.
Participants will be instructed to log their activities in real-time, including food intake and in-home BP monitoring using Fitbit and accompanied mobile app and BP monitor.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in blood pressure over time
Time Frame: Up to 8 weeks
|
Blood pressure (BP) will be measured using a Vital Signs Monitor 300 Series model (WelchAllyn, US).
The midsection circumference of the dominant upper arm will be measured with a tape measure, and the proper sized cuff will be selected accordingly.
Systolic and diastolic BP will be measured in the dominant arm twice with a 2-minute rest period between measures; two measures will be averaged.
|
Up to 8 weeks
|
|
Change in adherence to sodium restricted diet over time
Time Frame: Up to 8 weeks
|
Participants will complete a 24-hour urinary sodium excretion test at baseline and at 8 weeks after the intervention is completed.
24-hour urinary sodium excretion (mg excreted/day) will be tested by collecting all urine excreted over 24 hours.
Participants are asked to note the time when they start in a written log, then discard the first urine after that time.
They will then collect all urine excreted over the course of the next 24 hours, noting down the time and amount excreted each time in the written log.
Urine is stored in a container and does not need refrigeration.
24-hour urine sodium samples will be analyzed by the Center for Renal Precision Medicine laboratory.
|
Up to 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adherence to dietary sodium intake monitoring
Time Frame: Up to 8 weeks
|
Adherence to dietary sodium intake monitoring will be monitored using Fitbit companion mobile dietary app.
The Fitbit app is intended as an intervention tool to enhance self-monitoring and promote adherence, not a reliable assessment tool for dietary sodium intake (24-hour urinary samples will be used for that purpose as described in outcomes section).
Each subject will be registered to assign a unique ID in the platform developed by the Center on Smart and Connected Health Technologies at UT Health San Antonio, and each account from the individuals' Fitbit will be connected to his or her unique ID through this platform.
Subjects will be instructed to log their food intake in real-time.
Percentage of days that subject log his or her meal in the dietary app with a calorie intake of over 1000 will be used to measure adherence to dietary sodium intake monitoring.
|
Up to 8 weeks
|
|
Adherence to In-home BP monitoring
Time Frame: Up to 8 weeks
|
Adherence to In-home BP monitoring will be measured by the percentage of days that subject log in-home BP using a wireless and automatic BP monitor device (Omron 7 Series Upper Arm BP Monitor).
It has a range of 0 to 299 mmHg for BP and 40 to 180 beats per minute (bpm) for heart rate (HR).
The cuff is inflated using an electric pump and deflated by means of a pressure release valve.
After each measurement, the SBP, DBP, and HR are shown on the LCD screen.
The device can also display a symbol on the screen indicating an irregular heartbeat detected during measurement of SBP and DBP.
Each subject will be registered to assign a unique ID in the Connected Health Platform and each account from the individuals' Omron mobile app will be connected to his or her unique ID through this platform.
Subjects will be instructed to measure BP while in a sitting position and transfer the BP data to Omron mobile app using a wireless and automatic BP monitor device.
|
Up to 8 weeks
|
|
Attendance at education sessions
Time Frame: Up to 8 weeks
|
Attendance at education sessions will be measured by number of attended sessions for the 8-week education sessions in intervention group.
|
Up to 8 weeks
|
|
Retention rate
Time Frame: Up to 8 weeks
|
Retention rate will be measured by the percentage of subjects who come to the follow-up visit (8 weeks).
|
Up to 8 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jisook Ko, PhD, The University of Texas Health Science Center at San Antonio
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC20200504H
- KL2TR002646 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BackBeat Medical IncNot yet recruitingHypertension, Systolic | Hypertension (HTN) | Heart Failure With Preserved Ejection Fraction (HFpEFGeorgia
-
Xuanwu Hospital, BeijingNot yet recruiting
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Not yet recruiting
-
Instituto de Cardiologia do Rio Grande do SulCompletedHypertension (HTN) | Hypertension ArterialBrazil
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
Abant Izzet Baysal UniversityNot yet recruitingPRIMARY HYPERTENSIONTurkey (Türkiye)
-
SingHealth PolyclinicsNanyang PolytechnicEnrolling by invitationHypertension,EssentialSingapore
-
Hacettepe UniversityBozok UniversityCompletedHypertension | Arterial Hypertension | Systemic HypertensionTurkey (Türkiye)
Clinical Trials on Modified Sodium Watcher Program + Digital Self-Monitoring
-
Misook L. ChungCompleted
-
Mälardalen UniversityUppsala University; Uppsala University Hospital; Uppsala County Council, Sweden; Region Västmanland and other collaboratorsRecruitingBreast Cancer | Prostate Cancer | Neoadjuvant Therapy | Adjuvant Therapy | Colorectal Cancer (CRC)Sweden
-
National University of SingaporeRecruiting
-
Fooyin UniversityRecruitingGlucose Metabolism Disorders | Metabolic Diseases | Diabetes Mellitus | Endocrine System Diseases | Type 2 DiabetesTaiwan
-
University of ManitobaCompleted
-
Palo Alto Medical FoundationNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); American...CompletedObesity | Metabolic Syndrome | Pre-diabetesUnited States
-
University Hospital, ToulouseNot yet recruitingAdults With Acquired Brain InjuryFrance
-
The University of Texas Health Science Center at...The Rutgers Asian Resource Center for Minority Aging Research (RCMAR)Completed
-
University of AlbertaCompletedChronic Obstructive Pulmonary DiseaseCanada
-
University of WashingtonNational Center for Complementary and Integrative Health (NCCIH)Completed